
New phone system at TWINCORE
Some extension numbers have changed.

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.

Some extension numbers have changed.

zukunft.niedersachsen provides €2.7 million in funding for joint project on rare diseases

€100,000 from the German Society for Parkinson's Disease and Movement Disorders
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Mayer L, Arnold J, Roettele F, Reuter N, Pattekar A, Ohtani T, Ribeiro M, Siwicki R, Bruder K, Obwegs D, Stahl E, Buechel S, Roehlen N, Kolter J, Mansoori Moghadam Z, Alaswad A, Zhumalidova Z, Li G, Liu X, Li Y, Singh A, Villacorta Hidalgo J, Paraskevopoulou M, Yajnik V, Juarez J, Ren Y, Li H, Wherry E, Lewis J, Wu G, Bewtra M, Tomov V, Thimme R, Bengsch B, Hasselblatt P, Picelli S, Hofmann M, Sagar
Ilan S, Bartsch Y, Jung W, Kliuchnikov E, Roy V, Bonifer R, Walker-Sperling V, Borducchi E, Nkolola J, Lauffenburger D, Stieh D, Barouch D, Julg B
Koeken V, Nissen T, Birk N, Boahen C, van Crevel R, Kumar V, Li Y, Aaby P, Benn C, Netea M
The project is developing methods to specifically transport antibiotics into cells such as alveolar macrophages, which are important in Mycobacterium tuberculosis infections. The aim is to overcome resistance and reduce side effects.
In collaboration with the Department of Neurology and the Metabolomics Department, the project is investigating metabolic products in cerebrospinal fluid in order to identify biomarkers for CNS infections and cell damage and to distinguish long COVID and viral from autoimmune diseases.
Human, potentially neutralizing antibodies against HEV have advanced the development of new detection methods for the virus in patient samples. Serological and functional analyses are used to determine markers for the course and treatment of chronic infections.
We are investigating how genetic variants influence the risk of severe RSV infections in infants. Exome sequencing and bioinformatic analyses are used to identify causal variants in immunity genes.

